Astria Therapeutics, Inc. financial data

Symbol
ATXS on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1485% % -39%
Debt-to-equity 9% % 94%
Return On Equity -45% % -46%
Return On Assets -41% % -40%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57,084,838 shares 1.2%
Common Stock, Shares, Outstanding 56,434,894 shares 0%
Entity Public Float $370,232,653 USD 32%
Common Stock, Value, Issued $57,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 58,005,928 shares 0.32%
Weighted Average Number of Shares Outstanding, Diluted 58,005,928 shares 0.32%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $706,000 USD
General and Administrative Expense $39,175,000 USD 21%
Operating Income (Loss) $136,510,000 USD -18%
Nonoperating Income (Expense) $12,480,000 USD -23%
Net Income (Loss) Attributable to Parent $124,030,000 USD -24%
Earnings Per Share, Basic -2 USD/shares 0.92%
Earnings Per Share, Diluted -2 USD/shares 0.92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $96,280,000 USD 19%
Cash, Cash Equivalents, and Short-term Investments $227,700,000 USD -34%
Accounts Receivable, after Allowance for Credit Loss, Current $17,243,000 USD
Assets, Current $253,546,000 USD -28%
Operating Lease, Right-of-Use Asset $4,254,000 USD -21%
Other Assets, Noncurrent $14,066,000 USD 221%
Assets $271,866,000 USD -25%
Accounts Payable, Current $1,137,000 USD -11%
Employee-related Liabilities, Current $4,847,000 USD 34%
Accrued Liabilities, Current $16,481,000 USD 26%
Liabilities, Current $23,517,000 USD 50%
Operating Lease, Liability, Noncurrent $3,055,000 USD -28%
Liabilities $38,613,000 USD 93%
Accumulated Other Comprehensive Income (Loss), Net of Tax $56,000 USD -83%
Retained Earnings (Accumulated Deficit) $773,198,000 USD -19%
Stockholders' Equity Attributable to Parent $233,253,000 USD -32%
Liabilities and Equity $271,866,000 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,018,000 USD -78%
Net Cash Provided by (Used in) Financing Activities $141,807,000 USD 283%
Net Cash Provided by (Used in) Investing Activities $28,583,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 56,434,894 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,435,000 USD -54%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $96,280,000 USD 19%
Deferred Tax Assets, Valuation Allowance $153,529,000 USD 23%
Deferred Tax Assets, Gross $154,906,000 USD 24%
Operating Lease, Liability $4,459,000 USD -21%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $124,305,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid $5,045,000 USD -24%
Operating Lease, Liability, Current $1,404,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,640,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,608,000 USD 2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $586,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,531,000 USD -6.6%
Deferred Tax Assets, Operating Loss Carryforwards $93,650,000 USD 9.2%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,531,000 USD
Operating Lease, Payments $1,300,000 USD 30%
Additional Paid in Capital $911,014,000 USD 1.8%
Deferred Tax Assets, Net of Valuation Allowance $1,377,000 USD 1291%
Share-based Payment Arrangement, Expense $15,901,000 USD 25%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%